Category: by journal

“All very painful:” Two retractions to watch for, in eLife and PLOS ONE

We have news of two upcoming retractions, both following critiques on PubPeer.

PLOS ONE is retracting a 2012 paper by researchers at the Istituto Superiore di Sanità in Rome and the World Health Organization’s International Agency for Research on Cancer in Lyon, France, “Interferon-β Induces Cellular Senescence in Cutaneous Human Papilloma Virus-Transformed Human Keratinocytes by Affecting p53 Transactivating Activity.”

PubPeer commenters first left critiques of the paper on August 6 of last year, noting likely splicing and other manipulation of images. Several days later, pseudonymous whistleblower Claire Francis contacted the journal to flag similar issues. On Wednesday of this week, a journal representative emailed Francis to say the paper would be retracted: Continue reading “All very painful:” Two retractions to watch for, in eLife and PLOS ONE

Eyes wide shut at vision journal as retraction notice misses the point

Photo by Steve H.

Molecular Vision appears to have been flying blind when it retracted a 2013 paper by Rajendra Kadam and colleagues.

In December 2018, Kadam, a former “golden boy” in pharmaceutical research at the University of Colorado, Denver, was the subject of a finding from the U.S. Office of Research Integrity, which stated that he had fabricated his data. As part of the agreement, Kadam agreed to retract a paper in Molecular Vision. .

Kadam, who in 2016 had his doctoral degree revoked by UC Denver, two years after the university completed an investigation and sent its finding to the Office of Research Integrity (ORI), now has eight retractions, two expressions of concern and a correction. Seven of them mention fabrication of data. But Molecular Vision, the most recent addition to the list, does not.

The paper was titled “Suprachoroidal delivery in a rabbit ex vivo eye model: influence of drug properties, regional differences in delivery, and comparison with intravitreal and intracameral routes.” Its retraction notice, issued February 18, states: Continue reading Eyes wide shut at vision journal as retraction notice misses the point

Study claiming hate cuts 12 years off gay lives retracted

Low Library, Columbia University

After years of back and forth, a highly cited paper that appeared to show that gay people who live in areas where people were highly prejudiced against them had a significantly shorter life expectancy has been retracted.

The paper, “Structural stigma and all-cause mortality in sexual minority populations,”  was published in 2014 by Mark Hatzenbuehler of Columbia University and colleagues. As we reported last year, Mark Regnerus, of the University of Texas at Austin, published a paper describing his failed attempts to replicate the study in 2016: Continue reading Study claiming hate cuts 12 years off gay lives retracted

Why journal editors should dig deeper when authors ask for a retraction

Imagine you’re a journal editor. A group of authors sends you a request to retract one of their papers, saying that “during figure assembly certain images were inappropriately processed.”

What do you do next? Do you ask some tough questions about just what “inappropriately processed” means? Do you check your files for whether the author’s institution had told you about an investigation into the work? Do you Google the author’s names? Do you…search Retraction Watch?

It seems unlikely that any of those things happened in the case of a recent retraction from Nature Communications, or, if they did, they don’t seem to have informed the notice. We don’t know for sure, because, as is typical, the journal isn’t saying much. But here’s what we do know. Continue reading Why journal editors should dig deeper when authors ask for a retraction

Should journals credit eagle-eyed readers by name in retraction notices?

Logo of the European Society of Cardiology, EHJ’s publisher

One of the most highly-cited journals in cardiology has retracted a paper less than a month after publishing it in response to criticism first posted on Twitter.

The article, “Short-term and long-term effects of a loading dose of atorvastatin before percutaneous coronary intervention on major adverse cardiovascular events in patients with acute coronary syndrome: a meta-analysis of 13 randomized controlled trials,” was published online January 3 in the European Heart Journal (EHJ). Its authors purported to analyze clinical trials of patients who were given a loading dose of atorvastatin, a cholesterol medication, before undergoing cardiac catheterization.

How closely the study authors adhered to their own methods came under question on January 8, when Ricky Turgeon, a cardiology pharmacist, posted a series of tweets in which he claimed some of the studies included in the analysis either did not test the drug in patients undergoing the procedure — referred to as PCI — or patients had not all been diagnosed with acute coronary syndrome, commonly known as a heart attack. With many of the trials included in the analysis not abiding by the predefined inclusion criteria, the study’s conclusions are unreliable, argued Turgeon. Continue reading Should journals credit eagle-eyed readers by name in retraction notices?

Biochemist in Spain retracts eight papers at once

Carlos López-Otín

A high-profile researcher at the Universidad de Oviedo in Spain has retracted eight papers from the Journal of Biological Chemistry for figure issues.

All of the papers were co-authored by Carlos López-Otín, who studies a group of enzymes that break down proteins, cancer genomics and aging, and whose lab web site boasts that

His works have been collected in more than 400 articles in international journals and have been cited to date more than 44.000 times, with an aggregate Hirsch index of h=100.

A representative notice: Continue reading Biochemist in Spain retracts eight papers at once

After university goes silent, diabetes journal retracts three papers

A group of researchers based in Italy has had three papers retracted for likely using the same images to represent different experimental conditions.

The retractions, in Diabetes, published by the American Diabetes Association (ADA), follow expressions of concern for the papers in early 2018 and the launch of an investigation by the authors’ institution into the work. The status of that investigation by Università degli Studi di Napoli Federico II, however, is unclear, as the university has stopped responding to the journal’s inquiries.

Here are the three now-retracted papers: Continue reading After university goes silent, diabetes journal retracts three papers

“We regret our delay:” PLOS ONE retracts two papers

PLOS ONE has retracted two papers for image problems, which we’ve learned were brought to the journal’s attention more than four years ago.

The first article came from a group of cancer researchers in China, and it turns out to have a bit more wrong than a few dodgy figures. The second also involved cancer research.

Asked about the delay, PLOS ONE told Retraction Watch: Continue reading “We regret our delay:” PLOS ONE retracts two papers

After more than a year of back and forth, an accounting journal retracts a paper on tax avoidance

A pair of business researchers in Pittsburgh has lost a controversial 2017 paper on how institutional stock holdings affect tax strategies amid concerns about the validity of the data.

The article, “Governance and taxes: evidence from regression discontinuity,” which appeared in The Accounting Review, was written by Andrew Bird and Stephen Karolyi, of Carnegie Mellon’s Tepper School of Business.

According to the abstract: Continue reading After more than a year of back and forth, an accounting journal retracts a paper on tax avoidance

An Australian university cleared a cancer researcher of misconduct. He’s now retracted six papers.

Levon Khachigian

The story of Levon Khachigian’s research is a long and winding tale.

One place to start would be in October 2009, when a paper co-authored by Khachigian — whose work at the University of New South Wales (UNSW) has been funded by millions of dollars in funding from the Australian government, and has led to clinical trials, although more on that later — was retracted from Biochemical and Biophysical Research Communications. The “corresponding author published the paper without the full consent or acknowledgement of all the researchers and would like to apologize for this error,” according to that notice. Continue reading An Australian university cleared a cancer researcher of misconduct. He’s now retracted six papers.